NPF Expands Seal of Recognition to FDA-approved Treatments; First Seal Goes to Roflumilast 0.3% (Zoryve, Arcutis) June 2, 2025
PsO Pipeline Update: Enrollment Complete in Phase 3 Program of Alumis’ Oral TYK2 Inhibitor May 29, 2025
Switching Biologics in Psoriasis: First Person Dosed in New Study of Anti-IL-17 Treatment-Resistant Patients May 29, 2025
Expert Reaction: U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
U.S. FDA Gives Its Nod to Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
Accropeutics’ Oral Selective TYK2/JAK1 Inhibitor Performs Well in Phase 2 Study of Moderate-to-Severe Plaque PsO May 21, 2025
Residual Inflammation in Psoriasis Linked to Obesity, Fatty Liver Disease: Exploring Implications for Treatment May 20, 2025
Personalized Medicine in Psoriasis: Mindera Health’s Mind.Px Test Changes Physician Behavior, Improves Outcomes May 13, 2025
PsO Pipeline Watch: Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO May 9, 2025
